GlassScriptPhysician profile
Jonah Shulman
NPI 1669799920
$4,568.51
in general payments reported to CMS, 2019-2025
18 companies · $1,012 in 2025
The $1,012 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $1,219 · 2021: $137 · 2022: $1,665 · 2023: $142 · 2024: $246 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Consulting Fee: $650 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.47 |
| Consulting Fee | $650.00 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $1,802.32 | 2021-2022 | |
| Seagen INC. | $1,247.18 | 2019-2020 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Abbvie INC. | $171.02 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $161.76 | 2025 | Sylvant |
| Astrazeneca Pharmaceuticals LP | $149.31 | 2024-2025 | Calquence |
| Adc Therapeutics America, INC. | $141.59 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $119.44 | 2020 | |
| Kite Pharma, INC. | $70.99 | 2025 | Yescarta |
| Genmab U.S., INC. | $34.91 | 2024 | Epkinly |
| Pfizer INC. | $19.99 | 2025 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonah Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.